Killer, Alexander
Gliga, Smaranda http://orcid.org/0000-0001-8191-504X
Massion, Pascal
Ackermann, Carla
De Angelis, Clara
Flasshove, Charlotte
Freise, Noemi
Lübke, Nadine
Timm, Jörg
Eberhardt, Kirsten Alexandra
Bode, Johannes
Jensen, Björn-Erik Ole
Luedde, Tom
Orth, Hans Martin
Feldt, Torsten
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Article History
Received: 30 April 2024
Accepted: 12 August 2024
First Online: 29 August 2024
Declarations
:
: The authors declare no competing interest. AK did lectures for Gilead, received travel bursary from Gilead and Abbvie and a research grant from Gilead. BEOJ received consulting fees from Gilead, ViiV, Pfizer, MSD, Astra-Zeneca and Theratech; honoraria for presentations from Gilead, ViiV, GSK, Pfizer, MSD, Astra-Zeneca, Falk Foundation, Fresenius Medical Care. BEOJ was local principal investigator for Roche sponsored study on Tocilizumab (COVACTA, NCT04320615). NL received honoraria for lectures from Gilead, MSD, Abbvie, ViiV and served on advisory boards for ViiV and Theratechnologies. JT received honoraria for lectures from Novartis, GSK, Abbvie and served on advisory boards for Janssen-Cilag. TL received consulting fees from Gilead, Abbvie, and Ipsen; payment or honoraria for lectures or presentations from Gilead and Abbvie.
: All authors approved the publication of this manuscript.